BioNTech settles with NIH and UPenn over Comirnaty royalties, paying $750M to NIH and $400M to UPenn for 2020-2023, with ...

J&J partners with Kaken on STAT6 program, getting rights to KP-723 oral inhibitor. Kaken receives $30M upfront, potential $1.2B in milestone payments after Phase 1.

Bristol Myers Squibb's Sotyktu succeeds in Phase 3 psoriatic arthritis trials, as company leads TYK2 race against Takeda & ...

The Federal Trade Commission is praising an appeals court decision calling for Teva to delist five inhaler patents from the ...

The Centers for Medicare and Medicaid Services on Friday released detailed but heavily redacted explanations of how it ...

Amgen, Eli Lilly and UCB sued the federal government, claiming that several STD clinics getting drug discounts under the ...

The FDA on Friday issued two simultaneous cystic fibrosis approvals for Vertex Pharmaceuticals, but included boxed safety ...

Sumitomo Pharma’s oral treatment for overactive bladder symptoms has won an expanded label from the FDA, and is now approved ...

Generic drug firm Viatris announced Monday that one of its India-based manufacturing facilities has been placed on import ...

Novo Nordisk's CagriSema fell short of weight loss goals, causing 17% stock drop. Drug shows similar results to Eli Lilly's ...

FDA approves Novo Nordisk's Alhemo for hemophilia A and B with inhibitors. Once-daily shot reduces bleeding episodes in ...

GemmaBio, a company founded by gene therapy pioneer Jim Wilson, has raised $34 million in seed funding to try and resuscitate ...